AVDL vs BCRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while BCRX counters with relative strength in Valuation. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus BCRX at 8.4x Forward P/E and 48.8% operating margin (+13.1% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against BCRX sits in BREAKDOWN (10th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | BCRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.9B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | 16.8x | 12.4x | Lower Multiple | BCRX |
| Forward P/E Ratio Valuation | 28.8x | 8.4x | Lower Multiple | BCRX |
| Revenue Growth (YoY) Growth | +54.9% | +13.1% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | 48.8% | Higher Margin | BCRX |
| Net Profit Margin Profitability | -0.1% | -37.4% | Higher Margin | AVDL |
| Return on Equity (ROE) Capital Efficiency | -0.3% | -1925.4% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 20% ($6โ$11) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 0.66ฮฒ ยท 42% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 40.6 / 100 (SELL) | Higher Composite | AVDL |